Parathyroid Hormone 相關新聞

← 返回新聞總覽


Parathyroid Hormone 目前有 0 則相關新聞報導,預測適應症 20 個。

本頁整合 Parathyroid Hormone 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
  • 原適應症:Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
  • 證據等級:L5
  • 預測適應症(20 個):
    • migraine disorder(100.0%)
    • migraine with brainstem aura(100.0%)
    • amenorrhea (disease)(100.0%)
    • Raynaud disease(99.8%)
    • non-syndromic esophageal malformation(99.8%)
    • migraine with or without aura, susceptibility to(99.8%)
    • esophageal disease(99.7%)
    • atrophoderma vermiculata(99.7%)
    • ulerythema ophryogenesis(99.6%)
    • erectile dysfunction (disease)(99.1%)
    • esophageal ulcer(99.0%)
    • sciatic neuropathy(99.0%)
    • open-angle glaucoma(98.8%)
    • primary hereditary glaucoma(98.7%)
    • homozygous familial hypercholesterolemia(98.7%)
    • postural orthostatic tachycardia syndrome(98.7%)
    • lesion of sciatic nerve(98.6%)
    • infectious bovine rhinotracheitis(98.6%)
    • malignant catarrh(98.6%)
    • antithrombin deficiency type 2(98.5%)

查看完整藥物報告 →

相關新聞(0 則)

目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。

免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.